Why did GAAP EPS decline while adjusted EPS increased?

GAAP diluted EPS fell to $2.50 from $2.98 mainly because of acquisition-related intangibles amortization ($0.60 per share), restructuring and integration costs, a $35.5 million loss on divestiture of non-core businesses, and litigation and opioid expenses that were a credit in the prior-year quarter. Adjusted EPS excludes these items and rose to $3.73, a 13.7% increase.

What is driving the revenue growth?

Growth was driven primarily by unit volume in U.S. Healthcare Solutions, including increased sales of GLP-1 products for diabetes and weight loss and specialty products sold to physician practices and health systems. International Healthcare Solutions revenue grew 5.5%, led by its European distribution business.

Is the higher interest expense guidance a concern?

Net interest expense guidance rose to $290-$310 million from $150-$170 million, reflecting $1.8 billion of senior notes issued to finance the RCA acquisition and increased short-term borrowings. Investors should weigh this higher cost of capital against the acquisition's expected contribution to earnings and the company's rising debt load, which reached about $8.1 billion in total.

Why was operating cash flow negative this quarter?

Operating cash flow was negative $2.7 billion, compared with positive $885 million a year earlier. The shortfall reflects a $1.7 billion inventory build, a $974 million increase in receivables, and a $654 million decline in accounts payable. The company characterized the cash usage as largely seasonal working capital needs, which it funded through short-term borrowings.

Is the dividend safe, and what should shareholders expect?

The company declared a $0.55 quarterly dividend, payable March 3, 2025. With fiscal 2025 adjusted EPS guided to $15.25-$15.55, the annual dividend of $2.20 is covered roughly seven times on an adjusted basis. However, the negative operating cash flow this quarter and reduced total equity of $362 million warrant monitoring of cash generation in coming quarters.

COR 8-K: Earnings & Results & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed February 5, 2025. Cited figures are marked; the original filing is the authoritative source.

Cencora (COR) reported fiscal Q1 2025 results (quarter ended December 31, 2024) with revenue of $81.5 billion^a, up 12.8% year-over-year, driven by a 13.6% increase in U.S. Healthcare Solutions revenue.

GAAP diluted EPS was $2.50^b, down 16.1% from $2.98 a year earlier, while adjusted diluted EPS rose 13.7% to $3.73. The GAAP decline reflects higher operating expenses, including litigation and opioid-related expenses that swung from a credit last year, plus a $35.5 million loss on divestiture of non-core businesses and acquisition-related amortization. Gross margin compressed 28 basis points to 3.14%, largely due to lower-margin GLP-1 diabetes and weight-loss product sales and lower COVID-19 vaccine and exclusive therapy sales.

Management raised its fiscal 2025 adjusted diluted EPS guidance to $15.25^c-$15.55 from $15.15-$15.45, and lifted revenue growth guidance to 8-10% and adjusted operating income growth to 11.5-13.5%. The guidance raise is supported by momentum in U.S. Healthcare Solutions and the January 2, 2025 closing of the Retina Consultants of America acquisition. Investors should note that net interest expense guidance more than doubled to $290-$310 million, reflecting debt raised for the acquisition and seasonal working capital borrowings.

Operating cash flow was negative $2.7 billion^d in the quarter, driven by inventory build and receivables growth, and total debt rose sharply, with short-term debt of $2.2 billion and long-term debt of $5.9 billion. The company also declared a quarterly dividend of $0.55 per share, payable March 3, 2025, to holders of record on February 14, 2025.

Total equity fell to $362 million from $787 million at fiscal year-end, a figure investors may want to monitor alongside the leverage increase. The release is furnished under Item 2.02 and 7.01 rather than filed, so its contents are not subject to Section 18 liability.

02—Key points

Key Highlights

Revenue rose 12.8% year-over-year to $81.5 billion, led by a 13.6% increase in U.S. Healthcare Solutions to $74.0 billion.
GAAP diluted EPS fell 16.1% to $2.50, while adjusted diluted EPS grew 13.7% to $3.73, reflecting large non-GAAP adjustments including $164.9 million of acquisition-related amortization.
Fiscal 2025 adjusted diluted EPS guidance raised to $15.25-$15.55 from $15.15-$15.45; adjusted operating income growth guidance raised to 11.5-13.5%.
Net interest expense guidance increased to $290-$310 million from $150-$170 million, reflecting acquisition financing and borrowings.
Operating cash flow was negative $2.7 billion in the quarter due to inventory build and receivables growth; adjusted free cash flow usage was $2.85 billion.
Retina Consultants of America acquisition closed January 2, 2025, funded partly by $1.8 billion of senior notes issued in December 2024.
Quarterly dividend of $0.55 per share declared, payable March 3, 2025; diluted share count fell 3.3% to 195.2 million on buybacks.

03—Questions

Frequently Asked Questions

Why did GAAP EPS decline while adjusted EPS increased?
GAAP diluted EPS fell to $2.50 from $2.98 mainly because of acquisition-related intangibles amortization ($0.60 per share), restructuring and integration costs, a $35.5 million loss on divestiture of non-core businesses, and litigation and opioid expenses that were a credit in the prior-year quarter. Adjusted EPS excludes these items and rose to $3.73, a 13.7% increase.
What is driving the revenue growth?
Growth was driven primarily by unit volume in U.S. Healthcare Solutions, including increased sales of GLP-1 products for diabetes and weight loss and specialty products sold to physician practices and health systems. International Healthcare Solutions revenue grew 5.5%, led by its European distribution business.
Is the higher interest expense guidance a concern?
Net interest expense guidance rose to $290-$310 million from $150-$170 million, reflecting $1.8 billion of senior notes issued to finance the RCA acquisition and increased short-term borrowings. Investors should weigh this higher cost of capital against the acquisition's expected contribution to earnings and the company's rising debt load, which reached about $8.1 billion in total.
Why was operating cash flow negative this quarter?
Operating cash flow was negative $2.7 billion, compared with positive $885 million a year earlier. The shortfall reflects a $1.7 billion inventory build, a $974 million increase in receivables, and a $654 million decline in accounts payable. The company characterized the cash usage as largely seasonal working capital needs, which it funded through short-term borrowings.
Is the dividend safe, and what should shareholders expect?
The company declared a $0.55 quarterly dividend, payable March 3, 2025. With fiscal 2025 adjusted EPS guided to $15.25-$15.55, the annual dividend of $2.20 is covered roughly seven times on an adjusted basis. However, the negative operating cash flow this quarter and reduced total equity of $362 million warrant monitoring of cash generation in coming quarters.

04—Continue

← View all 8-K filings